Search
Tapinarof
go.drugbank.com/drugs/DB06083ApprovedInvestigationalTapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis. It is available as a topical cream to be applied to the affected area once daily. Tapiranof was first discovered as ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesFluorouracil
go.drugbank.com/drugs/DB00544ApprovedInvestigationalA pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: 5 FU, 5-FULevofloxacin
go.drugbank.com/drugs/DB01137ApprovedInvestigationalLevofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due
Synonyms: (3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid, (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acidCategories: P-glycoprotein inhibitors, P-glycoprotein substratesStiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigationalStiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs. … [A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes.
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsBrimapitide
go.drugbank.com/drugs/DB15231InvestigationalBrimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Daraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigationalDaraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma. … [L64039,L64041] Because it targets a broad range of RAS genotypes, it treats tumors with or without an identified RAS mutation and does not require a companion diagnostic test.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesVilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigational[L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support
Elacridar
go.drugbank.com/drugs/DB04881InvestigationalElacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. … In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline.
Categories: P-glycoprotein inhibitorsSerabelisib
go.drugbank.com/drugs/DB14935InvestigationalSerabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics
Phendimetrazine
go.drugbank.com/drugs/DB01579ApprovedIllicitPhendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.